This indicator reflects the percentage of women aged 15 to 49 who have given birth in the years leading up to the survey and received a minimum of three doses of sulfadoxine-pyrimethamine (SP/Fansidar) during their antenatal care (ANC) visits. Administered to pregnant women starting from the second trimester, this preventive strategy aims to combat malaria, which poses significant health risks during pregnancy. By ensuring that mothers receive this treatment at regular ANC check-ups—typically capped at one dose per month—this intervention is crucial not only for safeguarding maternal health but also for protecting newborns from the detrimental effects of malaria. Monitoring this percentage helps identify gaps in service delivery and inform public health policies aimed at improving maternal and infant outcomes.
Source: